Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL8380338 | 0.97 | TP53 (0.34) | TP53 | |
| SCHEMBL1135083 | 0.80 | TP53 (0.33) | TP53 | |
| SCHEMBL615604 | 0.80 | TP53 (0.33) | TP53 | |
| SCHEMBL28338994 | 0.79 | TP53 (0.32) | TP53 | |
| SCHEMBL4577140 | 0.78 | — | — | |
| SCHEMBL9066142 | 0.77 | TP53 (0.31) | TP53 | |
| SCHEMBL6850854 | 0.77 | SIGMAR1 (0.31) | TP53 | |
| Hydrochloric Acid SCHEMBL7205530 | 0.75 | MAPT (0.31) | MAPT | |
| Toluene SCHEMBL28914526 | 0.75 | LMNA (0.37) | — | |
| SCHEMBL7171976 | 0.72 | LTA4H (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1852408-B1 | PROCESS FOR THE DIMERIZATION OF ALPHA-OLEFINS | IDEMITSU KOSAN CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-20130225892-A1 | PROCESS FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2013-08-29 | — | — | US | disclosed |
| US-20120088946-A1 | PROCESS FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2012-04-12 | — | — | US | disclosed |
| US-8119850-B2 | Process for producing unsaturated hydrocarbon compound | IDEMITSU KOSAN CO., LTD. (JP) | 2012-02-21 | — | — | US | disclosed |
| US-20090069614-A1 | METHOD FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090030255-A1 | PROCESS FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1852408-A1 | PROCESS FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2007-11-07 | — | — | EP | disclosed |
| EP-1849757-A1 | METHOD FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | IDEMITSU KOSAN CO., LTD. (JP) | 2007-10-31 | — | — | EP | disclosed |
| EP-0891382-B1 | ALPHA-OLEFIN-CYCLOOLEFIN COPOLYMERS AND PROCESS FOR THEIR PRODUCTION | TEIJIN LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| US-6476153-B2 | INCLUDES A STEP OF DISTILLING UNREACTED DICYCLOPENTADIENE OR HYDROGENATED PRODUCT THEREOF, TETRAHYDRODICYCLOPENTADIENE FROM A MIXTURE OF THE COPOLYMER OR ITS HYDROGENATED PRODUCT IN THE PRESENCE OF A HIGH BOILING HYDROCARBON SOLVENT | TEIJIN LIMITED (JP) | 2002-11-05 | — | — | US | disclosed |
| US-6388032-B1 | SEPARATION BY FILTRATION | TEIJIN LIMITED (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20010009950-A1 | Process for producing hydrogenated alpha-olefin- dicyclopentadiene copolymer, method for molding the same and optical material | HASHIDZUME KIYONARI (JP) | 2001-07-26 | — | — | US | disclosed |
| US-6232407-B1 | MELT PROCESSABILITY | TEIJIN LIMITED (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6191243-B1 | ADDITION COPOLYMER HAVING HIGH DEGREE OF ALTERNATING ACYCLIC OLEFIN-DICYCLOPENTADIENE UNITS; OPTICAL RECORDING MEDIA SUBSTRATES | TEIJIN LIMITED (JP) | 2001-02-20 | — | — | US | disclosed |
| EP-1028128-A1 | CYCLOOLEFIN POLYMER REDUCED IN CATALYST RESIDUE CONTENT, USE THEREOF, AND PROCESS FOR PRODUCING THE SAME | TEIJIN LIMITED (JP) | 2000-08-16 | — | — | EP | disclosed |
| EP-0964005-A1 | Process for producing hydrogenated alpha-olefin-dicyclopentadiene copolymer, method for molding the same and optical material | TEIJIN LIMITED (JP) | 1999-12-15 | — | — | EP | disclosed |
| US-5916982-A | Process for the production of polyolefins | NIPPON OIL CO., LTD. (JP) | 1999-06-29 | — | — | US | disclosed |
| EP-0768320-A1 | Catalyst component and catalyst | NIPPON OIL CO. LTD. (JP) | 1997-04-16 | — | — | EP | disclosed |
| EP-0768319-A1 | Process for the production of polyolefins | NIPPON OIL CO. LTD. (JP) | 1997-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030255-A1 | PROCESS FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | ALOX12, ALOX15B, ALOX15 | TP53 4677/4885KDM4E 3798/4885CYP3A4 63/4885 |
| US-20090069614-A1 | METHOD FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | AHR, ALOX12, ARNT | TP53 3914/4885KDM4E 4610/4885CYP3A4 328/4885 |
| US-20120088946-A1 | PROCESS FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | ALOX12, ALOX15B, ALOX15 | TP53 4677/4885KDM4E 3798/4885CYP3A4 63/4885 |
| US-20130225892-A1 | PROCESS FOR PRODUCING UNSATURATED HYDROCARBON COMPOUND | ALOX12, ALOX15B, ALOX15 | TP53 4677/4885KDM4E 3798/4885CYP3A4 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.